Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coyle, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coyle, P. K.
NEUROLOGY 2007;68:S3-S7
© 2007 American Academy of Neurology

Evidence-based medicine and clinical trials

Patricia K. Coyle, MD

From the Loyola University Medical Center, Maywood, Illinois.

Address correspondence and reprint requests to Dr. Patricia K. Coyle, MS Comprehensive Care Center, SUNY at Stony Brook, HSC, T-12, NM020, Stony Brook, NY 11794 pcoyle{at}notes.cc.sunysb.edu

Optimal treatment of disease processes requires an objective assessment of clinical trial data in addition to careful patient monitoring. For multiple sclerosis (MS), the available treatments have been sufficiently evaluated in relapsing–remitting MS (RRMS), and physicians should treat MS patients to the standard of care recommended by the National Multiple Sclerosis Society and/or the American Academy of Neurology. In some cases, recommendations must be made in the absence of definitive clinical trial data. Physicians should understand the limitations of recommendations of this type and still apply a combination of careful clinical evaluation, assessment of patient and disease factors, and an objective evaluation of whatever clinical trial data are available when treatment decisions are made.


Disclosure: Dr. Coyle receives research funding and is a consultant to Berlex, Inc., Pfizer, Inc., Serono, Inc., and Teva Pharmaceuticals, Ltd. Dr Coyle also has Speaker’s Bureau agreements with or has received honoraria from Berlex, Inc., Pfizer Inc., Serono, Inc., and Teva Pharmaceuticals, Ltd. Publication of this supplement was supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Neurology® supplements are not peer-reviewed. Information contained in Neurology® supplements represents the opinions of the authors and is not endorsed by nor does it reflect the views of the American Academy of Neurology, Editorial Board, Editor-in-Chief, or Associate Editors of Neurology®.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.